Publications

FT500

2022 SITC Poster Presentation

Results of a Phase 1 Trial of FT500, a First-in-Class, Off-the-Shelf, iPSC-Derived NK Cell Therapy Combined with PD-1/PD-L1 Checkpoint Blockade Therapy and IL-2 in Patients with Advanced Solid Tumors

2020 SITC Poster

Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

Science Translational Medicine 2020; 12(568).

iPSC-Derived NK Cells Maintain High Cytotoxicity and Enhance In Vivo Tumor Control in Concert with T Cells and Anti–PD-1 Therapy
FT516

2022 SITC Poster Presentation

Phase 1 Results of FT516, an Off-the-Shelf, iPSC-Derived NK Cell Therapy Expressing a High-Affinity, Non-cleavable CD16 (hnCD16) Combined with Avelumab in Patients with Advanced Solid Tumors

2021 ASH Abstract

Phase I Study of FT516, an Off-the-Shelf, iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed / Refractory B-Cell Lymphoma

Blood. 2020; 135 (6): 399–410.

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
FT536

2022 SITC Poster Presentation

Combining FT536, a pan-Tumor Targeting CAR NK Cell Therapy, with CD16 Engagers Provides a Coordinated Targeting Strategy to Overcome Tumor Heterogeneity

2022 ASGCT Presentation

FT536: A First-of-Kind, Off-the-Shelf CAR-iNK Cell Product Candidate for Solid Tumors Designed to Specifically Target MICA/B Stress Proteins and Overcome Mechanisms of Tumor Evasion

2021 SITC Abstract

FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy

Cancer Immunol Res 2020; 8:769–80.

Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells
FT596

2021 ASH Abstract

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

2021 ASH Abstract

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed / Refractory B-Cell Lymphoma

New England Journal of Medicine. 2020; 382: 545–53.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
FT538

2022 SITC Poster Presentation

Interim Phase 1 Clinical Data of FT538, on Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy, Combined with Monoclonal Antibodies in Patients with Advanced Solid Tumors

Cancer Stem Cell Publication

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy

2021 SITC Abstract

Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo

2020 ASH Poster Presentation – Manufacturing

cGMP Mass Production of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line

2020 ASH Poster Presentation – Clinical

A Phase I Study of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered, iPSC Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma
FT576

2020 ASH Poster Presentation

FT576: Multi specific Off the Shelf CAR NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self Fratricide and Optimized mAb Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
FT873/FT573

2022 SITC Poster Presentation

Targeting cold tumors using iPSC-derived CAR T Cells directed to the immune checkpoint molecule and tumor-associated antigen B7-H3

2022 AACR Poster

FT573: Preclinical Development of Multiplexed-Engineered iPSC-derived NK Cells Expressing a Novel Camelid Nanobody Chimeric Antigen Receptor (CAR) Targeting pan-Cancer Antigen B7-H3
FT819

2021 ASH Abstract

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

2019 ASH Abstract

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Nature Medicine. 2019; 25: 82–88.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
iPSC Product Platform

2022 SITC Poster Presentation

iPSC-derived NK cells Engineered with a Novel TGFβ signal Redirector Receptor Exhibit Enhanced Performance Against Solid Tumors
Trimodal CAR+TCR+hnCD16+ iPSC-derived T Cells Co-Targeting Surface and Intracellular/Neoantigens Demonstrate Additive Effect on Overcoming Tumor Heterogeneity and Cancer Escape
Novel Immune Reconstitution Model Highlights the Importance of Stealth Strategies that Potentiate Effector Cell Function and Promote Functional Persistence of Next-Generation Adoptive Cell Therapies
Off-the-Shelf iPSC-derived CAR-T cells Targeting KLK2 Demonstrate Prolonged Tumor Control and Survival in Xenograft Models of Prostate Cancer
Off-the-Shelf iPSC-derived CAR-T cells Containing Seven Functional Edits Overcome Antigen Heterogeneity, Improve Trafficking, and Withstand Immunosuppression Associated with Failed Tumor Treatment
Engineering of Synthetic Chemokine Receptors into iPSC-derived CAR-T cells to Increase Homing and Enhance Trafficking into Solid Tumors
Preclinical in vivo Model Development: Highlighting Success and Discussing Xenograft Advancements, a Step Closer in Predicting Patient Outcomes

2022 AACR Posters

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy
Chimeric CD3 Fusion Receptors Expressed on iPSC-derived Universal TCR-less CAR-T and -NK Cells Synergize with Bispecific Engagers to Enhance Antitumor Activity and Limit Antigen Escape
Novel Combination of iPSC-derived Dual Dual -CAR NK Cells with CD16 Fc Receptor for Multi-antigen Targeting of Multiple Myeloma to Overcome Clonal Resistance and Antigen Escape
Multiplexed-engineered, iPSC-derived T Cells Expressing Three Unique Targeting Modalities Address Tumor Heterogeneity and Antigen Escape
Detection of Genetically Engineered iPSC-derived Natural Killer Cells in Blood and Tissue

2022 ASGCT Posters

Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications
Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies
Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors
Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy
10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization
Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells
iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy

2021 SITC Abstract

Synthetic redirection of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors
Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors

2021 ASH Abstract

Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma
Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection
Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Stem Cell Reporst

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells